Sustainability at
Fresenius Medical Care 

Our full Sustainability Statement provides detailed information on our strategy, performance, and progress. We are reporting in accordance with the European Sustainability Reporting Standards (ESRS) for the 2025 financial year. The topics reported on were identified with a double materiality assessment. 

At Fresenius Medical Care, sustainability supports our vision of Creating a future worth living.
For patients. Worldwide. Every day.  

As the world’s leading provider of products and services for people with chronic kidney failure, millions of patients rely on our clinics, products, and teams several times a week. Delivering this life-sustaining care requires safe, reliable operations, supported by strong systems, responsible resource use, and the people who deliver and support it.

That is why sustainability is embedded in how we operate — not treated as a separate initiative. It is linked to our corporate strategy, FME Reignite, which focuses on strengthening the core of our care delivery, enabling growth and innovation, and developing our people and culture.

For our sustainability priorities, we concentrate on three key areas:

Sustainability in action 

Here are some highlights of how sustainability supported patients, our people, and operations in 2025. We continued integrating sustainability into our strategy and day-to-day operations — reinforcing care quality, workforce stability, and operational resilience.

Advancing care for patients

Technology and data-driven quality improvements


Improving outcomes for people living with kidney disease depends on strong clinical practice supported by the right data at the right time. With 25 ongoing or completed clinical studies and 190 published scientific research documents, we advanced medical knowledge and shared valuable healthcare insights.

Across our global network, we operate more than 30 AI and analytics-driven tools that enhance data accessibility, strengthen quality monitoring, and support timely, more consistent treatment decisions. These tools combine advanced analytics, predictive modeling, and digital decision-support systems to help care teams identify risks earlier and respond proactively. They are designed to support clinical judgment, not replace it.

Recent initiatives include:

  • predictive models to identify potential clinical risks
  • AskHUGO, a tool supporting physicians with Hemodiafiltration (HDF) prescriptions
  • an AI-powered nutrition tool helping patients create personalized meal plans 

By making outcomes more visible and actionable, these digital tools support patients and help physicians in their care for patients.

Our patients in the US also benefit from our ReferralReady workflow through which we sent approximately 62,000 referrals to transplantation centers in 2025. The IT platform aggregates multiple patient related data points into a single document that can be efficiently assembled and electronically delivered to the transplant center. 

 

 

Progress in 2025

73

Global patient Net Promoter Score increased in 2025, reflecting a strong patient experience

62,000

Transplant referrals in the U.S.

175,000+

Patients in the US under our care as of end of 2025 evaluated for food security, addressing health related social needs of our patients

25

Ongoing or completed clinical studies

Driving sustainable operations and design 

Climate strategy and progress on protecting the environment


Dialysis care depends on energy, water, and operational resilience. In 2025, our climate targets were validated by the Science Based Targets initiative (SBTi). Alongside our 2030 targets for scope 1 and 2, as well as scope 3 targets, we adopted a long-term net-zero target for 2050 covering scopes 1, 2, and 3.

Against our baseline year 2020, we have reduced over 29% of the emissions footprint of our own operations (scope 1 and 2), and are on track to meet our 2030 target to reduce these emissions by 50% over this timeframe. This year, we are reporting progress against our 2030 scope 3 targets for the first time.

We advanced energy-efficiency initiatives at production sites and expanded renewable electricity sourcing. In 2025, we completed more than 90 environmental projects as part of our Green & Lean initiative at our production sites to prevent greenhouse gas emissions, save water and energy, and improve recycling and reuse of waste. These actions support efficiency in resource use while strengthening operational resilience.

 

 

Progress in 2025

Net-zero by 2050

SBTi-validated commitment to reduce scope 1, 2, and 3 emissions

29%

CO2e emissions footprint reduction in own operations against 2020 baseline

106,9 million m3

Amount of reused or recycled water increased

100%

Defined revenue scope covered by our Portfolio Sustainability Assessment

31%

Of hazardous and non-hazardous waste recycled

Empowering our people to contribute to a sustainable future

Reigniting our values


Sustainable healthcare depends on the people who deliver it. Our refreshed company values ‘We care. We connect. We commit’ and cultural behaviors align more directly with the priorities of our new FME Reignite strategy. Building on insights drawn from structured employee input that included 70 focus groups with approximately 300 employees in 19 countries. Through regional workshops, leadership discussions, and targeted focus sessions across functions and levels — we clarified the behaviors that shape how we collaborate, make decisions, and take ownership day-to‑day. These refreshed values are being embedded into leadership development, performance management, and our daily ways of working. 

 

 

Progress in 2025

  
66
%

Employee engagement score increased in 2025

Strategy & Values

Sustainability was embedded into our new strategy and refreshed values, which were rolled out globally.


Nearly 
1,200

Employees in need supported through the CARES fund


64 hours 

Of training on average per employee